The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Open accessAbstract
Kidney fibrosis is the final common pathway of all progressive chronic kidney diseases, of which diabetic nephropathy is the leading cause. Endothelial-to-mesenchymal transition (EndMT) has emerged as one of the most important origins of matrix-producing fibroblasts. Dipeptidyl peptidase-4 (DPP-4) inhibitors have been introduced into the market as antidiabetes drugs. Here, we found that the DPP-4 inhibitor linagliptin ameliorated kidney fibrosis in diabetic mice without altering the blood glucose levels associated with the inhibition of EndMT and the restoration of microRNA 29s. Streptozotocin-induced diabetic CD-1 mice exhibited kidney fibrosis and strong immunoreactivity for DPP-4 by 24 weeks after the onset of diabetes. At 20 weeks after the onset of diabetes, mice were treated with linagliptin for 4 weeks. Linagliptin-treated diabetic mice exhibited a suppression of DPP-4 activity/protein expression and an amelioration of kidney fibrosis associated with the inhibition of EndMT. The therapeutic effects of linagliptin on diabetic kidneys were associated with the suppression of profibrotic programs, as assessed by mRNA microarray analysis. We found that the induction of DPP-4 observed in diabetic kidneys may be associated with suppressed levels of microRNA 29s in diabetic mice; linagliptin restored microRNA 29s and suppressed DPP-4 protein levels. Using cultured endothelial cells, we found that linagliptin inhibited TGF-β2–induced EndMT, and such anti-EndMT effects of linagliptin were mediated through microRNA 29 induction. These results indicate the possible novel pleiotropic action of linagliptin to restore normal kidney function in diabetic patients with renal impairment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Endothelial-to-mesenchymal transition contributes to cardiac fibrosis
Zeisberg, E. M., Tarnavski, O., Zeisberg, M., Dorfman, A. L., McMullen, J. R., Gustafsson, E., Chandraker, A., Yuan, X., Pu, W. T., Roberts, A. B., et al. (2007) · Nature Medicine · doi:10.1038/nm1613 · Cited by 2,222
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A., & Olson, E. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805038105 · Cited by 1,844
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Origin and function of myofibroblasts in kidney fibrosis
LeBleu, V. S., Taduri, G., O'Connell, J., Teng, Y., Cooke, V. G., Woda, C., Sugimoto, H., & Kalluri, R. (2013) · Nature Medicine · doi:10.1038/nm.3218 · Cited by 1,263
Tubulointerstitial Changes as a Major Determinant in the Progression of Renal Damage
Nath, K. A. (1992) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80312-x · Cited by 974
Risdon, R. A., Sloper, J. C., & De Wardener, H. E. (1968) · The Lancet · doi:10.1016/s0140-6736(68)90589-8 · Cited by 668
The role of endothelial-to-mesenchymal transition in cancer progression
Potenta, S., Zeisberg, E., & Kalluri, R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604662 · Cited by 554
miR-29 Is a Major Regulator of Genes Associated with Pulmonary Fibrosis
Cushing, L., Kuang, P. P., Qian, J., Shao, F., Wu, J., Little, F., Thannickal, V. J., Cardoso, W. V., & Lü, J. (2011) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2010-0323oc · Cited by 502
Jarett, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92801-9 · Cited by 495
Structural-functional correlations in renal disease
Schainuck, L. I., Striker, G. E., Cutler, R. E., & Benditt, E. P. (1970) · Human Pathology · doi:10.1016/s0046-8177(70)80061-2 · Cited by 462
Groop, P.-H., Cooper, M. E., Perkovic, V., Emser, A., Woerle, H.-J., & von Eynatten, M. (2013) · Diabetes Care · doi:10.2337/dc13-0323 · Cited by 294
Pharmacokinetics of dipeptidylpeptidase‐4 inhibitors
Scheen, A. J. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01212.x · Cited by 281
Liu, Y., Taylor, N. E., Lu, L., Usa, K., Cowley, A. W., Ferreri, N. R., Yeo, N. C., & Liang, M. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.144428 · Cited by 235
Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis
Kanasaki, K., Taduri, G., & Koya, D. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00007 · Cited by 227
Self-citationBroxmeyer, H. E., Hoggatt, J., O'Leary, H. A., Mantel, C., Chitteti, B. R., Cooper, S., Messina-Graham, S., Hangoc, G., Farag, S., Rohrabaugh, S. L., et al. (2012) · Nature Medicine · doi:10.1038/nm.2991 · Cited by 223
Sugimoto, H., Grahovac, G., Zeisberg, M., & Kalluri, R. (2007) · Diabetes · doi:10.2337/db06-1226 · Cited by 211
Dipeptidyl Peptidase IV Inhibitor Attenuates Kidney Injury in Streptozotocin-Induced Diabetic Rats
Liu, W. J., Xie, S. H., Liu, Y. N., Kim, W., Jin, H. Y., Park, S. K., Shao, Y. M., & Park, T. S. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.186866 · Cited by 209
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Casrouge, A., Decalf, J., Ahloulay, M., Lababidi, C., Mansour, H., Vallet-Pichard, A., Mallet, V., Mottez, E., Mapes, J., Fontanet, A., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci40594 · Cited by 189
The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans
Blech, S., Ludwig-Schwellinger, E., Gräfe-Mody, E. U., Withopf, B., & Wagner, K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.031476 · Cited by 189
Mackensen‐Haen, S., Bader, R., Grund, K. E., & Bohle, A. (1981) · PubMed · Cited by 188
High glucose down‐regulates miR‐29a to increase collagen IV production in HK‐2 cells
Du, B., Ma, L.-M., Huang, M.-B., Zhou, H., Huang, H.-L., Shao, P., Chen, Y.-Q., & Qu, L.-H. (2010) · FEBS Letters · doi:10.1016/j.febslet.2009.12.053 · Cited by 168
Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease
He, J., Xu, Y., Koya, D., & Kanasaki, K. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0781-0 · Cited by 167
Self-citationRegulation of Fibroblast Migration on Collagenous Matrix by a Cell Surface Peptidase Complex
Ghersi, G., Dong, H., Goldstein, L. A., Yeh, Y., Hakkinen, L., Larjava, H. S., & Chen, W.-T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202770200 · Cited by 166
Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Experimental Diabetes Research · doi:10.1155/2011/279530 · Cited by 138
Kaji, K., Yoshiji, H., Ikenaka, Y., Noguchi, R., Aihara, Y., Douhara, A., Moriya, K., Kawaratani, H., Shirai, Y., Yoshii, J., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0783-4 · Cited by 135
Therapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 115
Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity
Kern, M., Klöting, N., Niessen, H. G., Thomas, L. H., Stiller, D., Mark, M., Klein, T., & Blüher, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038744 · Cited by 110
Ta, N., Li, Y., Schuyler, C. A., Lopes-Virella, M. F., & Huang, Y. Q. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.08.064 · Cited by 96
Des-serine-proline brain natriuretic peptide 3–32 in cardiorenal regulation
Boerrigter, G., Costello‐Boerrigter, L. C., Harty, G. J., et al. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00569.2006 · Cited by 96
Effects of DPP-4 inhibition on cardiac metabolism and function in mice
Lenski, M., Kazakov, A., Marx, N., Böhm, M., & Laufs, U. (2011) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2011.08.001 · Cited by 84
Yang, J., Campitelli, J., Hu, G., Lin, Y., Luo, J. J., & Xue, C. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.04.040 · Cited by 81
Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy
Chaykovska, L., von Websky, K., Rahnenführer, J., Alter, M., Heiden, S., Fuchs, H., Runge, F. E., Klein, T., & Hocher, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027861 · Cited by 81
Connelly, K. A., Zhang, Y., Advani, A., Advani, S. L., Thai, K., Yuen, D. A., & Gilbert, R. E. (2012) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12005 · Cited by 67
Arscott, W. T., LaBauve, A. E., May, V., & Wesley, U. V. (2008) · Oncogene · doi:10.1038/onc.2008.402 · Cited by 63
Pathophysiology of the aging kidney and therapeutic interventions
Kanasaki, K., Kitada, M., & Koya, D. (2012) · Hypertension Research · doi:10.1038/hr.2012.159 · Cited by 62
Self-citationTakahashi, A., Asakura, M., Ito, S., Min, K.-D., Shindo, K., Yan, Y., Liao, Y., Yamazaki, S., Sanada, S., Asano, Y., et al. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00454.2012 · Cited by 61
Diabetic angiopathy and angiogenic defects
Xu, L., Kanasaki, K., Kitada, M., & Koya, D. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-13 · Cited by 60
Self-citation
Cited by
Endothelial to Mesenchymal Transition: Role in Physiology and in the Pathogenesis of Human Diseases
Piera-Velazquez, S., & Jimenez, S. A. (2019) · Physiological Reviews · doi:10.1152/physrev.00021.2018 · Cited by 662
Macro‐ and microvascular endothelial dysfunction in diabetes: 糖尿病诱导的内皮细胞功能损伤
Shi, Y., & Vanhoutte, P. M. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12521 · Cited by 545
Endothelium structure and function in kidney health and disease
Jourde-Chiche, N., Fakhouri, F., Dou, L., Bellien, J., Burtey, S., Frimat, M., Jarrot, P.-A., Kaplanski, G., Le Quintrec, M., Pernin, V., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0098-z · Cited by 493
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Muskiet, M. H. A., Tonneijck, L., Smits, M. M., van Baar, M. J. B., Kramer, M. H. H., Hoorn, E. J., Joles, J. A., & van Raalte, D. H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.123 · Cited by 407
Cho, J. G., Lee, A., Chang, W., Lee, M.-S., & Kim, J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00294 · Cited by 284
Metadata
- Authors
- Kanasaki, K., Shi, S., Kanasaki, M., He, J., Nagai, T., Nakamura, Y., Ishigaki, Y., Kitada, M., Srivastava, S. P., & Koya, D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-05-15
- Volume
- 63
- Issue
- 6
- Pages
- 2120-2131
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2116878783
- Cited by
- 359
- References
- 38
- FWCI
- 24.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.